Skip to content

Gisèle Pickering

University Hospital Clermont-Ferrand, Inserm CIC 1405, Platform of Clinical Investigation, Platform of Clinical Investigation, F-63000 Clermont-Ferrand, France.

2 papers in the library · 4 citations · publishing 2025

Papers

Managing Chronic Pain: The Ketamine Option

CNS Drugs October 16, 2025 Gisèle Pickering, Véronique Morel, Marion Voute 2 citations

Ketamine, an anesthetic and sedative drug, is used off-label for chronic refractory pain and can provide significant short-term pain relief, especially for neuropathic pain, and is fairly well-tolerated in patients with severe refractory pain. However, long-term data on efficacy, cognitive impact, addiction risk, and optimal dosing are severely lacking. The intravenous route is the most studied, while alternatives remain underexplored. Ketamine is not a first-line treatment and must be prescribed by trained specialists within a structured standard of care. Future use depends on collaborative research to define optimal administration routes, patient phenotyping, and long-term studies assessing mood, quality of life, and cognitive function.

Sex and Age Differences in Ketamine Efficacy and Safety in Chronic Pain Alleviation.

Journal of clinical medicine June 16, 2025 Gisèle Pickering, Marion Voute, Marc Sorel et al. 2 citations

A one-year observational study of 585 chronic pain patients found no sex or age differences in how well ketamine relieved pain, anxiety, or depression. Women reported more adverse events than men (19% vs. 13%). Among 329 patients who received two or more doses, no sex or age differences appeared. A single ketamine dose may be more effective for men than women, particularly younger men.